Innate Pharma

Research Innate Pharma (IPHA) on Bullrun: market cap USD 169.03M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIPHA
• ExchangeNASDAQ
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 169.03M
• Financial periodFY2025
• RevenueUSD 2.79M
• Revenue growth-77.9%
• Net income-USD 49.18M
• Free cash flow-USD 34.91M

Valuation Snapshot

latest market cap is USD 169.03M.

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.

Frequently asked questions

What is Innate Pharma's market cap?

Innate Pharma's market capitalization is USD 169.03M.

What does Innate Pharma do?

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.